Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.
- Authors
- Rodriguez-Abreu, D[Rodriguez-Abreu, Delvys]; Gray, JE[Elaine Gray, Jhanelle]; Ahn, MJ[Ahn, Myung-Ju]; Johnson, ML[Lynne Johnson, Melissa]; Yu, XW[Yu, Xinwei]; Chen, XY[Chen, Xueying]; Phuong, PH[Hoang Phuong, Patrick]; Kim, J[Kim, Jongseok]; Reck, M[Reck, Martin]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.